Update shared on05 Sep 2025
With both the Future P/E (81.49x to 81.41x) and Net Profit Margin (2.08%) remaining essentially stable, there has been no material change in fundamentals, and accordingly, the consensus Analyst Price Target for SBI Life Insurance remains unchanged at ₹2082.
What's in the News
- AU Small Finance Bank partnered with SBI Life Insurance to distribute a full suite of life insurance products across over 2,500 banking touchpoints in 21 states and 4 union territories, targeting underserved and emerging markets in India.
- The collaboration supports nationwide financial protection and aligns with the government's 'Insurance for All by 2047' initiative.
- SBI Life's board scheduled a meeting to consider and approve audited financial results for the quarter ended June 30, 2025.
Valuation Changes
Summary of Valuation Changes for SBI Life Insurance
- The Consensus Analyst Price Target remained effectively unchanged, at ₹2082.
- The Future P/E for SBI Life Insurance remained effectively unchanged, moving only marginally from 81.49x to 81.41x.
- The Net Profit Margin for SBI Life Insurance remained effectively unchanged, at 2.08%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.